Cargando…

Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry

AIMS: Digoxin is included in some heart failure (HF) guidelines but controversy persists about the true role for and impact of treatment with this drug, particularly in the absence of atrial fibrillation (AF). The aim of this study was to assess the association between clinical characteristics and d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapelios, Chris J, Lund, Lars H, Benson, Lina, Dahlström, Ulf, Rosano, Giuseppe M C, Hauptman, Paul J, Savarese, Gianluigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716867/ https://www.ncbi.nlm.nih.gov/pubmed/34921603 http://dx.doi.org/10.1093/ehjcvp/pvab079

Ejemplares similares

Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry
por: Lindberg, Felix, et al.
Publicado: (2022)

Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry
por: D'Amario, Domenico, et al.
Publicado: (2022)

Corrigendum to: Digoxin use in contemporary heart failure with reduced ejection fraction: An analysis from the Swedish Heart Failure Registry
Publicado: (2023)

Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction
por: Stolfo, Davide, et al.
Publicado: (2023)

Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real‐world data from the Swedish Heart Failure Registry
por: Savarese, G., et al.
Publicado: (2020)

The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Persistent High Burden of Heart Failure Across the Ejection Fraction Spectrum in a Nationwide Setting
por: Stolfo, Davide, et al.
Publicado: (2022)

Epidemiology, Clinical Characteristics and Cause-specific Outcomes in Heart Failure with Preserved Ejection Fraction
por: Kapelios, Chris J, et al.
Publicado: (2023)

A registry‐based algorithm to predict ejection fraction in patients with heart failure
por: Uijl, Alicia, et al.
Publicado: (2020)

Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata
por: Stolfo, Davide, et al.
Publicado: (2022)

Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization
por: Savarese, Gianluigi, et al.
Publicado: (2019)

Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry
por: Ergatoudes, Constantinos, et al.
Publicado: (2019)

Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure
por: Lindberg, Felix, et al.
Publicado: (2022)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction
por: Löfström, Ulrika, et al.
Publicado: (2019)

Predictors of primary prevention implantable cardioverter‐defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all‐cause mortality
por: Schrage, Benedikt, et al.
Publicado: (2022)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

“Real World” Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry
por: Simpson, Joanne, et al.
Publicado: (2019)

Association between heart failure quality of care and mortality: a population‐based cohort study using nationwide registries
por: Batra, Gorav, et al.
Publicado: (2022)

Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction
por: Uijl, Alicia, et al.
Publicado: (2021)

Global Public Health Burden of Heart Failure: An Updated Review
por: Shahim, Bahira, et al.
Publicado: (2023)

Cardiac resynchronization therapy with or without defibrillator in patients with heart failure
por: Schrage, Benedikt, et al.
Publicado: (2021)

Digoxin is associated with worse outcomes in patients with heart failure with reduced ejection fraction
por: Zhou, Jingmin, et al.
Publicado: (2020)

Risk of stroke in patients with heart failure and sinus rhythm: data from the Swedish Heart Failure Registry
por: Hjalmarsson, Clara, et al.
Publicado: (2020)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
por: Shahim, Angiza, et al.
Publicado: (2023)

Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2022)

Ethnic differences in the association of QRS duration with ejection fraction and outcome in heart failure
por: Gijsberts, Crystel M, et al.
Publicado: (2016)

Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register
por: Eriksson, Björn, et al.
Publicado: (2019)

Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction
por: Straw, Sam, et al.
Publicado: (2021)

Participation in a clinical trial is associated with lower mortality but not lower risk of HF hospitalization in patients with heart failure: observations from the ESC EORP Heart Failure Long-Term Registry
por: Kapelios, Chris J, et al.
Publicado: (2023)

Use of Renin–Angiotensin–Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction
por: Stolfo, Davide, et al.
Publicado: (2019)

Impact of Digoxin Use on Guideline-Directed Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction
por: Jabri, Ahmad, et al.
Publicado: (2022)

Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
por: Rahamim, Eldad, et al.
Publicado: (2021)

Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction
por: Vishram-Nielsen, Julie K. K., et al.
Publicado: (2022)

Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart Failure Long‐Term Registry
por: Kapłon‐Cieślicka, Agnieszka, et al.
Publicado: (2020)

Management of heart failure with reduced ejection fraction in Europe: design of the ARIADNE registry
por: Zeymer, Uwe, et al.
Publicado: (2020)

Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
por: Egbuche, Obiora, et al.
Publicado: (2020)

Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly
por: Milinković, Ivan, et al.
Publicado: (2022)

Clinical profile and contemporary management of patients with heart failure with preserved ejection fraction: results from the CHECK-HF registry
por: Uijl, A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nt83kg3634q93f6f3773el73sr